Abstract:Yan Jin, 1, 2, &ast Ke Zhu, 1, &ast Shiyu Wu, 1 Shiyi He, 1 Chao Cao 1 1 Department of Respiratory and Critical Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Municipal Hospital Affiliated to Taizhou University, Taizhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chao Cao, Email Background: Epidemiologic studies have shown that patients with acute exacerbation of COPD (AECOPD) suffer from morbidity and mortality from venous thromboembolism (VTE) and poor diagnosis. Von Willebrand factor (vWF) and plasminogen activator inhibitor type-1 (PAI-1) are frequently investigated in COPD as crucial parameters for coagulation and fibrinolysis. Nevertheless, the role of vWF and PAI-1 in AECOPD needs further exploration. Objective: We sought to evaluate the hypercoagulability in AECOPD and investigate the association of plasma vWF and PAI-1 with occurrence and exacerbation risk of AECOPD patients. Methods: Fifty-seven AECOPD patients and 34 control subjects were enrolled in our study. The concentrations of plasma vWF and PAI-1 antigens were measured by ELISA kit. Independent samples t -test or Wilcoxon rank sum test was applied for group comparison. Spearman correlation analysis, subject work curve (ROC) analysis, and Logistic regression were used to evaluate the role of the plasma vWF and PAI-1 in AECOPD. Results: We observed increased vWF (770.15 ± 325.52 vs 327.62 ± 210.97 ng/mL, P < 0.001) and PAI-1 (0.47 vs 0.17 ng/mL, P < 0.001) levels in AECOPD patients compared with control subjects. Both vWF and PAI-1 are closely related to COPD (vWF: AUC = 0.8741, P < 0.001; PAI-1: AUC = 0.8222, P < 0.001). Moreover, elevated vWF could be an independent risk factor for COPD (OR = 1.01, 95% CI: 1.00– 1.01, P = 0.01). We also discovered higher plasma levels of vWF and PAI-1 in the COPD "E" group in contract to "AB" group (vWF: 966.29 ± 251.18 vs 552.21 ± 253.28, P < 0.0001; PAI-1: 1.02 vs 0.38, P = 0.003). And vWF levels increased with increasing COPD exacerbation risk, moreover, plasma vWF positively related with patients' CAT scores and SGRQ scores. In addition, plasma vWF and PAI-1 correlated with each other in total participants and AECOPD subgroup analysis. Conclusion: This study demonstrated that AECOPD patients have a prothrombotic state, as demonstrated by vWF and PAI-1 levels in plasma compared with those in control subjects, and the prothrombotic state increases with increasing COPD exacerbation risk. Keywords: chronic obstructive pulmonary disease, exacerbation, vWF, PAI-1, coagulation, fibrinolysis Chronic obstructive pulmonary disease (COPD), one of the chronic respiratory diseases (CRDs), is a heterogeneous pulmonary condition characterized by chronic respiratory symptoms (such as dyspnea, cough, and sputum production) associated with airway abnormalities (bronchitis, bronchiolitis) and/or alveoli (emphysema) that contribute to persistent, progressive and aggravated airflow obstruction. 1 Until now, COPD remains an increasingly important cause of morbidity, disability, and mortality worldwide, associated with a substantial burden and cost. 2–4 Once the diagnosis of COPD has been established by spirometry, the GOLD ABE assessment tool is applied to the initial assessment of COPD to guide therapy. COPD patients will be divided into ABE subgroups according to the levels of symptoms and history of exacerbations in the previous year. Moreover, exacerbation is regarded as the independent risk factor for the prognosis of COPD patients, which is associated with more significant morbidity and mortality. 5,6 Inpatients with AECOPD are at increased risk for vascular events, 7–9 including venous thromboembolism (VTE), an umbrella term of deep venous thrombosis (DVT) and pulmonary embolism (PE). 10,11 Furthermore, COPD patients are at 2–3 times greater risk for cardiovascular mortality risk factor for the prognosis of COPD patients, which risk factor for the prognosis of COPD patients, which. 12 Clinicians should therefore be confident in approaching the patient with suspected VTE. Although VTE scoring and routine detection of hemostatic parameters (APTT, PT, TT, FIB) are widely used in clinical practice, the incidence of vascular events in COPD patients is still underestimated, which affects patients' prognosis and increases mortality. Consequently, more clinical tests need to be carried out to help predict the VTE r -Abstract Truncated-

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function

Elevated Circulating PAI-1 Levels Are Related to Lung Function Decline, Systemic Inflammation, and Small Airway Obstruction in Chronic Obstructive Pulmonary Disease.

Urokinase-Type Plasminogen Activator System and Human Cationic Antimicrobial Protein 18 in Serum and Induced Sputum of Patients with Chronic Obstructive Pulmonary Disease

Levels of Components of the Urokinase-Type Plasminogen Activator System Are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling

Plasminogen Activator Inhibitor-1 Promotes Inflammatory Process Induced by Cigarette Smoke Extraction or Lipopolysaccharides in Alveolar Epithelial Cells.

The Curious Role of PAI-1 in Severe Obstructive Sleep Apnea

Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease

Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis.

Biomarkers of Prothrombotic State and Risk Assessment of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease

Blood PAI-1 and cardiovascular and metabolic risk factors among the middle-aged women from SWAN study

P6450Plasminogen activator inhibitor type-1 (PAI-1) expression relates to the presence of myocardial inflammation in patients with nonischemic cardiomyopathy

Genome-wide Association Study for Circulating Levels of Plasminogen Activator Inhibitor-1 (PAI-1) Provides Novel Insights into the Regulation of PAI-1 Running Title: HUANG Et Al., GENETIC LOCI ASSOCIATED WITH PAI-1

Atherosclerosis is Associated with Plasminogen Activator Inhibitor Type-1 in Chronic Haemodialysis Patients

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

Association of innate defense proteins BPIFA1 and BPIFB1 with disease severity in COPD

Relationship Between Pulmonary Arterial Hypertension and Fibrinolysis in Elder Patients with Chronic Obstructive Pulmonary Disease

Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza A virus infection-induced lung injury

Critical Roles of PAI-1 in Lipopolysaccharide-Induced Acute Lung Injury.

Increased Plasminogen Activator Inhibitor-1 Concentrations in Bronchoalveolar Lavage Fluids Are Associated with Increased Mortality in a Cohort of Patients with Pseudomonas Aeruginosa.

TIMP-1: A Circulating Biomarker for Pulmonary Hypertension Diagnosis Among Chronic Obstructive Pulmonary Disease Patients

Serum Levels of Plasminogen Activator Inhibitor-1 in Patients with Parkinson's Disease